3SBio Inc., a leading biopharmaceutical company headquartered in China, has established itself as a key player in the biotechnology industry since its founding in 1993. With a strong operational presence across major regions in Asia, 3SBio focuses on the development, manufacturing, and marketing of innovative therapies, particularly in the fields of oncology, nephrology, and autoimmune diseases. The company is renowned for its core products, including recombinant human erythropoietin and other biologics, which are distinguished by their high quality and efficacy. Over the years, 3SBio has achieved significant milestones, including successful product launches and strategic partnerships, solidifying its market position as a trusted provider of biopharmaceutical solutions. With a commitment to advancing healthcare, 3SBio continues to drive innovation and improve patient outcomes in the biopharmaceutical landscape.
How does 3sbio's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
3sbio's score of 21 is lower than 80% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, 3SBio, headquartered in China (CN), reported total carbon emissions of approximately 60,649,530 kg CO2e. This figure includes 11,663,450 kg CO2e from Scope 1 emissions and 48,986,080 kg CO2e from Scope 2 emissions. The company has shown a significant increase in emissions compared to 2022, when total emissions were about 45,896,560 kg CO2e, comprising 7,257,230 kg CO2e from Scope 1 and 38,639,330 kg CO2e from Scope 2. 3SBio has not disclosed any Scope 3 emissions data, and there are currently no documented reduction targets or climate pledges. The absence of specific reduction initiatives indicates a potential area for future commitment in line with industry standards for climate action. The emissions data is sourced directly from 3SBio Inc., with no cascading from a parent or related organization. Overall, while 3SBio has made strides in reporting its emissions, the lack of reduction targets suggests an opportunity for enhanced climate commitments moving forward.
Access structured emissions data, company-specific emission factors, and source documents
2019 | 2020 | 2021 | 2022 | |
---|---|---|---|---|
Scope 1 | 5,960,680 | 0,000,000 | 0,000,000 | 0,000,000 |
Scope 2 | 42,724,590 | 00,000,000 | 00,000,000 | 00,000,000 |
Scope 3 | - | - | - | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
3sbio is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.